Hythiam to receive patent for treatment of cocaine dependency

The patent will serve to enhance protection of the intellectual property underlying the company’s Promet treatment program for cocaine dependence, and follows the granting of cocaine patents in other major markets over the past 12 months, including the US, Europe, Japan and Korea.

Hythiam’s Promet treatment program is designed for use by healthcare providers seeking to treat individuals diagnosed with dependencies to alcohol, cocaine or methamphetamine, as well as combinations of these drugs.

Terren Peizer, chairman and CEO of Hythiam, said: “Our intellectual property portfolio continues to grow in strength and value. Addiction is a global problem and Russia is one of the world’s largest emerging economies. By securing our patent rights throughout the world, we stand ready to capture the commercial benefit on behalf of our shareholders.”